Philip T. Cagle & Timothy Craig Allen 
Precision Molecular Pathology of Lung Cancer 

This new edition provides the latest information and insights into the molecular basis for lung cancer. Since the publication of the previous edition of this volume, dramatic changes have occurred with the classification of lung cancer, biomarker testing, and molecular therapy. The book covers these changes, providing updates and new insights on the background of lung cancer, testing methods, and the molecular pathology of specific cell types, including adenocarcinoma, squamous cell carcinoma, small cell carcinoma, and precursor and preinvasive lesions.






Authored by experts in the field,
Precision Molecular Pathology of Lung Cancer, Second Edition remains one of the few books that comprehensively covers the new molecular pathology of lung cancer and is a valuable resource for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, and thoracic radiologists.

Table of Content

I. Background.- 1. Precision Medicine of Lung Cancer: Introduction.- 2. Lung Cancer Epidemiology and Demographics.- 3. Genetic Susceptibility to Lung Cancer.- 4. Lung Cancer Stem Cells.- 5. The 2015 World Health Organization Classification of Lung Cancer: Overview.- II. Testing Methods.- 6. Preanalytic considerations.- 7. Mutation testing of lung cancer biomarkers.- 8. Translocation testing of lung cancer biomarkers.- 9. Immunohistochemistry of lung cancer biomarkers.- 10. Next Generation and Third Generation Sequencing of lung cancer biomarkers.- III. Molecular Pathology of Specific Cell Types.- 11. Mutations as Predictive Biomarkers for Adenocarcinoma.- 12. Translocations as predictive Biomarkers for Adenocarcinoma.- 13. Predictive Biomarkers for Squamous Cell Carcinoma.- 14. Molecular Pathology of Small Cell Carcinoma.- 15. Molecular Pathology of Uncommon Carcinomas.- 16. Molecular Pathology of Lung Cancer Metastases.- 17. Molecular Pathology of Precursor and Preinvasive Lesions.- IV. General and Emerging Fields in Molecular Pathology of Lung Cancer.- 18. Prognostic biomarkers in lung cancer.- 19. Biomarkers and Differing Therapy Modalities.- 20. Immuno-oncology of Lung Cancer.- 21. Liquid Biopsy.

About the author

Philip T. Cagle, MD
Houston Methodist Hospital
Department of Pathology & Genomic Medicine
6565 Fannin St
Houston, TX 77030

Timothy C. Allen, MD
The University of Texas Medical Branch 
Department of Pathology
301 University Boulevard
Galveston, TX 77555

Mary Beth Beasley, MD
Mount Sinai Hospital

Department of Pathology
1468 Madison Avenue
New York, NY 10029

Lucian R. Chirieac, MD
Brigham And Women’s Hospital
Department of Pathology
75 Francis St.
Boston, MA 02115

Sanja Dacic, MD, Ph D
University of Pittsburgh Medical Center
Department of Pathology
200 Lothrop St.

Pittsburgh, PA 15213

Alain C. Borczuk, MD
Weill Cornell University Medical Center
Department of Pathology
1300 York Avenue
Starr-1000A
New York, NY 10065

Keith M. Kerr, MD
Aberdeen University Medical School
Aberdeen Royal Infirmary
Department of Pathology
Foresterhill

Aberdeen, Scotland

Lynette Sholl, MD
Brigham And Women’s Hospital
Department of Pathology
75 Francis St
Boston, MA 02115

Bryce Portier, MD
Houston Methodist Hospital
Department of Pathology & Genomic Medicine
6565 Fannin St
Houston, TX 77030



Eric Bernicker, MD

Houston Methodist Hospital
Thoracic Medical Oncology
6445 Main St, Floor 21
Houston, TX 77030